• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磺酰脲受体的C末端尾巴控制ADP诱导的ATP敏感性钾通道的激活以及二氮嗪对其的调节。

C-terminal tails of sulfonylurea receptors control ADP-induced activation and diazoxide modulation of ATP-sensitive K(+) channels.

作者信息

Matsuoka T, Matsushita K, Katayama Y, Fujita A, Inageda K, Tanemoto M, Inanobe A, Yamashita S, Matsuzawa Y, Kurachi Y

机构信息

Departments of Pharmacology II, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

出版信息

Circ Res. 2000 Nov 10;87(10):873-80. doi: 10.1161/01.res.87.10.873.

DOI:10.1161/01.res.87.10.873
PMID:11073882
Abstract

The ATP-sensitive K(+) (K(ATP)) channels are composed of the pore-forming K(+) channel Kir6.0 and different sulfonylurea receptors (SURs). SUR1, SUR2A, and SUR2B are sulfonylurea receptors that are characteristic for pancreatic, cardiac, and vascular smooth muscle-type K(ATP) channels, respectively. The structural elements of SURs that are responsible for their different characteristics have not been entirely determined. Here we report that the 42 amino acid segment at the C-terminal tail of SURs plays a critical role in the differential activation of different SUR-K(ATP) channels by ADP and diazoxide. In inside-out patches of human embryonic kidney 293T cells coexpressing distinct SURs and Kir6.2, much higher concentrations of ADP were needed to activate channels that contained SUR2A than SUR1 or SUR2B. In all types of K(ATP) channels, diazoxide increased potency but not efficacy of ADP to evoke channel activation. Replacement of the C-terminal segment of SUR1 with that of SUR2A inhibited ADP-mediated channel activation and reduced diazoxide modulation. Point mutations of the second nucleotide-binding domains (NBD2) of SUR1 and SUR2B, which would prevent ADP binding or ATP hydrolysis, showed similar effects. It is therefore suggested that the C-terminal segment of SUR2A possesses an inhibitory effect on NBD2-mediated ADP-induced channel activation, which underlies the differential effects of ADP and diazoxide on K(ATP) channels containing different SURs.

摘要

ATP敏感性钾(K(ATP))通道由形成孔道的钾通道Kir6.0和不同的磺脲类受体(SURs)组成。SUR1、SUR2A和SUR2B分别是胰腺、心脏和血管平滑肌型K(ATP)通道特有的磺脲类受体。导致它们具有不同特性的SURs结构元件尚未完全确定。在此我们报告,SURs C末端尾部的42个氨基酸片段在不同SUR-K(ATP)通道被ADP和二氮嗪的差异激活中起关键作用。在共表达不同SURs和Kir6.2的人胚肾293T细胞的内向外膜片中,激活含有SUR2A的通道所需的ADP浓度比激活含有SUR1或SUR2B的通道所需的浓度高得多。在所有类型的K(ATP)通道中,二氮嗪增加了ADP诱发通道激活的效力但不增加其效能。用SUR2A的C末端片段替换SUR1的C末端片段可抑制ADP介导的通道激活并降低二氮嗪的调节作用。SUR1和SUR2B的第二个核苷酸结合结构域(NBD2)的点突变,这会阻止ADP结合或ATP水解,显示出类似的效果。因此表明,SUR2A的C末端片段对NBD2介导的ADP诱导的通道激活具有抑制作用,这是ADP和二氮嗪对含有不同SURs的K(ATP)通道产生不同作用的基础。

相似文献

1
C-terminal tails of sulfonylurea receptors control ADP-induced activation and diazoxide modulation of ATP-sensitive K(+) channels.磺酰脲受体的C末端尾巴控制ADP诱导的ATP敏感性钾通道的激活以及二氮嗪对其的调节。
Circ Res. 2000 Nov 10;87(10):873-80. doi: 10.1161/01.res.87.10.873.
2
Intramolecular interaction of SUR2 subtypes for intracellular ADP-Induced differential control of K(ATP) channels.SUR2亚型的分子内相互作用对细胞内ADP诱导的K(ATP)通道的差异调控
Circ Res. 2002 Mar 22;90(5):554-61. doi: 10.1161/01.res.0000012666.42782.30.
3
[Activation of ATP-sensitive K+ channels by ADP and K+ channel openers: homology model of sulfonylurea receptor carboxyl-termini].[ADP及钾通道开放剂对ATP敏感性钾通道的激活作用:磺脲类受体羧基末端的同源模型]
Nihon Yakurigaku Zasshi. 2001 Sep;118(3):177-86. doi: 10.1254/fpj.118.177.
4
Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.钾通道开放剂需要ATP与磺脲类受体结合并通过该受体起作用。
EMBO J. 1998 Oct 1;17(19):5529-35. doi: 10.1093/emboj/17.19.5529.
5
MCC-134, a novel vascular relaxing agent, is an inverse agonist for the pancreatic-type ATP-sensitive K(+) channel.MCC - 134是一种新型血管舒张剂,是胰腺型ATP敏感性钾通道的反向激动剂。
J Pharmacol Exp Ther. 2000 Jan;292(1):131-5.
6
Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP.ADP揭示心脏ATP敏感性钾通道对二氮嗪的药理学可塑性。
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12162-7. doi: 10.1073/pnas.96.21.12162.
7
Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels.天然线粒体ATP敏感性钾通道与分子定义的表面ATP敏感性钾通道的药理学比较。
Mol Pharmacol. 2001 Feb;59(2):225-30.
8
Different binding properties and affinities for ATP and ADP among sulfonylurea receptor subtypes, SUR1, SUR2A, and SUR2B.磺脲类受体亚型SUR1、SUR2A和SUR2B对ATP和ADP具有不同的结合特性及亲和力。
J Biol Chem. 2000 Sep 15;275(37):28757-63. doi: 10.1074/jbc.M004818200.
9
ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP.ATP敏感性钾通道调节剂与磺脲类受体SUR2A和SUR2B的结合:MgADP的相反作用
Mol Pharmacol. 1999 May;55(5):832-40.
10
Modulation of the trafficking efficiency and functional properties of ATP-sensitive potassium channels through a single amino acid in the sulfonylurea receptor.通过磺脲类受体中的单个氨基酸对ATP敏感性钾通道的转运效率和功能特性进行调节。
J Biol Chem. 2003 Feb 28;278(9):7081-90. doi: 10.1074/jbc.M211395200. Epub 2002 Dec 21.

引用本文的文献

1
ATP-gated potassium channels contribute to ketogenic diet-mediated analgesia in mice.ATP门控钾通道有助于生酮饮食介导的小鼠镇痛作用。
Neurobiol Pain. 2023 Jul 3;14:100138. doi: 10.1016/j.ynpai.2023.100138. eCollection 2023 Aug-Dec.
2
Pulmonary hypertension associated with diazoxide: the SUR1 paradox.与二氮嗪相关的肺动脉高压:SUR1 悖论。
ERJ Open Res. 2023 Nov 13;9(6). doi: 10.1183/23120541.00350-2023. eCollection 2023 Nov.
3
Rapid Characterization of the Functional and Pharmacological Consequences of Cantú Syndrome K Channel Mutations in Intact Cells.
快速鉴定完整细胞中 Cantú 综合征钾通道突变的功能和药理学后果。
J Pharmacol Exp Ther. 2023 Sep;386(3):298-309. doi: 10.1124/jpet.123.001659. Epub 2023 Aug 1.
4
The inhibition mechanism of the SUR2A-containing K channel by a regulatory helix.含 SUR2A 的 K 通道受调节螺旋抑制的机制。
Nat Commun. 2023 Jun 17;14(1):3608. doi: 10.1038/s41467-023-39379-4.
5
Personalized Therapeutics for K-Dependent Pathologies.个体化治疗依赖 K 的病理。
Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:541-563. doi: 10.1146/annurev-pharmtox-051921-123023. Epub 2022 Sep 28.
6
Structural identification of vasodilator binding sites on the SUR2 subunit.血管扩张剂结合部位在 SUR2 亚基上的结构鉴定。
Nat Commun. 2022 May 13;13(1):2675. doi: 10.1038/s41467-022-30428-y.
7
Comparison of K Channel Families.钾通道家族的比较。
Handb Exp Pharmacol. 2021;267:1-49. doi: 10.1007/164_2021_460.
8
Structure based analysis of K channel with a DEND syndrome mutation in murine skeletal muscle.基于结构的分析,具有 DEND 综合征突变的 K 通道在鼠骨骼肌中。
Sci Rep. 2021 Mar 23;11(1):6668. doi: 10.1038/s41598-021-86121-5.
9
K Channel Openers Inhibit Lymphatic Contractions and Lymph Flow as a Possible Mechanism of Peripheral Edema.K 通道开放剂抑制淋巴收缩和淋巴液流动,可能是外周水肿的机制之一。
J Pharmacol Exp Ther. 2021 Jan;376(1):40-50. doi: 10.1124/jpet.120.000121. Epub 2020 Oct 25.
10
Uncoupling a unique couple by chopping off one of its tails: insights into the K channels of the heart and pancreas.切断独特配对中的一条“尾巴”来解开配对:对心脏和胰腺钾通道的见解
J Physiol. 2018 Dec;596(24):6135-6136. doi: 10.1113/JP277099. Epub 2018 Nov 28.